Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
about
Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesGlitazone Treatment and Incidence of Parkinson's Disease among People with Diabetes: A Retrospective Cohort StudyThiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality.Serum glucose and hemoglobin A1C levels at cancer diagnosis and disease outcome.Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.Reappraisal of risk factors for monoclonal gammopathy of undetermined significance.Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.Pioglitazone Use and Risk of Bladder Cancer: an In Vitro Study.Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis.
P2860
Q27025423-63A1C7C2-8751-4764-9A6A-3EB362CA77CFQ28546721-2323CBEB-48EF-4615-B8FB-958EB524CBB1Q34315432-D5699516-C89F-4DD2-A16C-3DA2B421C984Q35817986-C7ADDFFC-7097-47E8-8C93-8BC6765505A9Q36853961-14D14D1F-2233-4873-A5DC-3CC5F50FB767Q38417421-2D03FA0C-25A3-452C-995A-52BACDD04280Q38641190-E6B42FED-4972-4DAC-B179-F37781734EDDQ40141299-55AE8D6B-4E61-45A7-A00B-0373A2FB09BCQ53199621-DDCEB8ED-7B8C-4615-9DE1-1398329F54E0Q55079635-0BEE5493-82C3-4A17-B8E0-37C2DC7FA7F6Q55356554-FE600B5C-6232-472E-85ED-A37F2F5996B5Q55406042-5E35C8C9-16F6-44B7-B1C7-987BF25FE958
P2860
Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Proteinuria testing among pati ...... oglitazone and bladder cancer.
@en
Proteinuria testing among pati ...... oglitazone and bladder cancer.
@nl
type
label
Proteinuria testing among pati ...... oglitazone and bladder cancer.
@en
Proteinuria testing among pati ...... oglitazone and bladder cancer.
@nl
prefLabel
Proteinuria testing among pati ...... oglitazone and bladder cancer.
@en
Proteinuria testing among pati ...... oglitazone and bladder cancer.
@nl
P2093
P2860
P356
P1476
Proteinuria testing among pati ...... ioglitazone and bladder cancer
@en
P2093
Brian L Strom
Charles Quesenberry
David J Vaughn
James D Lewis
Lisa Nessel
Monique Hedderson
Ronac Mamtani
Tiffany Peng
Warren B Bilker
P2860
P304
P356
10.1002/PDS.3619
P577
2014-04-25T00:00:00Z